Sign Up Today and Learn More About SiteOne Therapeutics Stock
Invest in or calculate the value of your shares in SiteOne Therapeutics or other pre-IPO companies through EquityZen's platform.
SiteOne Therapeutics Stock (SITA)
SiteOne Therapeutics is a biopharmaceutical company that develops pain therapeutics to treat sensory hyperexcitability disorders.
About SiteOne Therapeutics Stock
Founded
2010
Headquarters
Bozeman, MT, US
Industries
Messaging and Telecommunications, Sports, Content and Publishing
SiteOne Therapeutics Press Mentions
Stay in the know about the latest news on SiteOne Therapeutics
Voltage-activated sodium bicyclic heterocyclic amide 1.8 (NAV1.8) inhibitors …
patents • Apr 02, 2025
NAV1.7 NON-HYDRATED KETONE INHIBITORS FOR THE TREATMENT OF PAIN
patents • Apr 02, 2025
Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
patents • Feb 07, 2025
11,13-modified saxitoxins for the treatment of pain
patents • Feb 07, 2025
Funding Is Flush For Startups Focused On Treating Pain
news • Feb 05, 2025
SiteOne Therapeutics Management
Leadership team at SiteOne Therapeutics
Board Member
Will Price
Board Member
Mona Ashiya
Join now and verify your accreditation status to gain access to:
- SiteOne Therapeutics Current Valuation
- SiteOne Therapeutics Stock Price
- SiteOne Therapeutics Management
- Available deals in SiteOne Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- SiteOne Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- SiteOne Therapeutics Revenue and Financials
- SiteOne Therapeutics Highlights
- SiteOne Therapeutics Business Model
- SiteOne Therapeutics Risk Factors
- SiteOne Therapeutics Research Report from SACRA Research
Trading SiteOne Therapeutics Stock
How to invest in SiteOne Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like SiteOne Therapeutics through EquityZen funds. These investments are made available by existing SiteOne Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell SiteOne Therapeutics stock?
Shareholders can sell their SiteOne Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
